IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Inspire Investing LLC

Inspire Investing LLC trimmed its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 13.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 19,045 shares of the medical research company’s stock after selling 3,069 shares during the period. Inspire Investing LLC’s holdings in IQVIA were worth $4,027,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Rise Advisors LLC acquired a new stake in shares of IQVIA in the first quarter valued at approximately $31,000. Versant Capital Management Inc grew its holdings in IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after buying an additional 110 shares during the last quarter. Riverview Trust Co purchased a new position in IQVIA during the first quarter worth $32,000. Opal Wealth Advisors LLC acquired a new position in shares of IQVIA in the second quarter worth $27,000. Finally, International Assets Investment Management LLC purchased a new stake in shares of IQVIA in the second quarter valued at $32,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Morgan Stanley boosted their target price on shares of IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, July 23rd. Argus raised shares of IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Truist Financial lifted their target price on shares of IQVIA from $292.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Robert W. Baird increased their price target on IQVIA from $235.00 to $251.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 23rd. Finally, JPMorgan Chase & Co. lifted their price objective on IQVIA from $260.00 to $288.00 and gave the company an “overweight” rating in a research report on Monday, August 5th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $266.67.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at $4,812,302.88. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 1.60% of the stock is owned by company insiders.

IQVIA Price Performance

IQVIA stock opened at $242.67 on Thursday. The firm has a fifty day moving average of $239.74 and a 200-day moving average of $234.18. IQVIA Holdings Inc. has a 52-week low of $167.42 and a 52-week high of $261.73. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. The firm has a market capitalization of $44.21 billion, a P/E ratio of 33.15, a PEG ratio of 2.24 and a beta of 1.49.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating the consensus estimate of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The company had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. During the same period last year, the company posted $2.22 earnings per share. The firm’s revenue was up 2.3% compared to the same quarter last year. As a group, analysts predict that IQVIA Holdings Inc. will post 10.25 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.